Biotech Investors Eye Cystic Fibrosis Trials and Rare-Disease Drugs
Biotech investors are closely watching cystic fibrosis drug trials, rare-disease therapies and regulatory catalysts. Sionna Therapeutics is advancing a new CF drug class, while Praxis Precision Medicines targets essential tremor. FDA staffing challenges add uncertainty to approval timelines.
Biotech investors are closely watching companies advancing treatments for cystic fibrosis, neurological disorders and rare diseases as clinical trial milestones and regulatory reviews approach. Sionna Therapeutics is developing a completely new drug class of cystic fibrosis drugs that targets the underlying CFTR mutation, with Phase 2 data expected mid-year on a key biomarker that could tell whether the drug could be life-changing for many cystic fibrosis patients. About two-thirds of patients do not reach normal CFTR channel function on the current standard of care.
Vertex Pharmaceuticals, the developer of the current standard-of-care cystic fibrosis therapies, markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.
Praxis Precision Medicines is entering a product cycle with its lead drug ulixacaltamide for essential tremor, a condition that affects more than two million patients in North America. There are no approved branded therapies that target it to a degree that makes a meaningful difference in patients' lives.
Regulatory engagement remains critical as drug developers navigate staffing challenges and shifting dynamics within the U.S. Food and Drug Administration. The FDA has had staffing issues, and the division and HHS have had significant leadership turnover and staffing turnover.
Other biotech stocks with the highest dollar trading volume include Danaher Corporation, which offers bioprocess technologies, consumables, and services that advance the development and manufacture of therapeutics; United Therapeutics Corporation, which markets Tyvaso DPI, Tyvaso, Remodulin, Orenitram, and Adcirca for pulmonary arterial hypertension; argenx SE, whose lead product candidate efgartigimod is being developed for multiple autoimmune conditions; Moderna, Inc., which develops mRNA therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, autoimmune and cardiovascular diseases; ImmunityBio, a clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system; Cocrystal Pharma, focused on structure-based antiviral drug discovery; and Medpace Holdings, which provides outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries.